5330-66-5

Usage

Uses

Due to the limited information provided about the safety, environmental impact, and specific applications of 1-(2-Nitrophenoxy)acetone, it is difficult to list its uses in various industries. However, based on its properties, it can be inferred that it may be used in the following ways:
Used in Chemical Synthesis:
1-(2-Nitrophenoxy)acetone is used as a reagent for various chemical reactions due to its unique reactivity and the presence of both organic and inorganic components.
Used in Industrial Processes:
1-(2-Nitrophenoxy)acetone is used as a solvent in certain industrial processes, taking advantage of the solvent properties of its acetone component.

InChI:InChI=1/C9H9NO4/c1-7(11)6-14-9-5-3-2-4-8(9)10(12)13/h2-5H,6H2,1H3

Upstream product

• 13414-54-5 2-[(2-methyl-2-propenyl)oxy]-1-nitrobenzene 
• 598-31-2 1-bromoacetone 
• 88-75-5 2-hydroxynitrobenzene 
• 78-95-5 chloroacetone 
• 67-64-1 acetone 
• 1666-18-8 4-Chlor-benzolsulfonsaeure-acetolester 
• 824-39-5 sodium o-nitrophenate 
• 824-38-4 potassium 2-nitrophenoxide 
• 1124-31-8 potassium 4-nitrophenolate 

Downstream Products

• 32329-20-7 (RS)-3-methyl-3,4-dihydro-2H-[1,4]benzoxazine 
• 854666-04-9 1-(2-aminophenoxy)propan-2-ol 
• 98730-04-2 4-dichloroacetyl-3,4-dihydro-3-methyl-2H-1,4-benzoxazine 

Relevant academic research and scientific papers

Synthesis, Crystal Structure, and Biological Activity of 4-phenoxyacetyl-substituted methyl-3,4-dihydro-2H-1,4-benzoxazine

Two novel substituted benzoxazine derivatives have been synthesized through reduction, cyclization, and acylation reactions. The target compounds were characterized by IR, 1H-NMR, 13C-NMR, and HRMS. The single-crystal structures of t

TBAI/TBHP mediated oxidative cross coupling of ketones with phenols and carboxylic acids: Direct access to benzofurans

TBAI/TBHP mediated oxidative cross coupling of phenols and carboxylic acids with ketones has been reported under metal-free, base free, solvent free conditions enabling environmentally benign synthesis of aryloxyketones, acyloxy ketones and benzofurans. Phenoxyketones and acyloxylcarbonyl compounds were synthesized in good to high yields, where as benzofurans were synthesized in moderate yields. This method is operationally simple, works under mild conditions, using commercially available as well as inexpensive TBAI and an oxidant TBHP.

Chemoenzymatic Asymmetric Synthesis of 1,4-Benzoxazine Derivatives: Application in the Synthesis of a Levofloxacin Precursor

A versatile and general route has been developed for the asymmetric synthesis of a wide family of 3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazines bearing different pattern substitutions in the aromatic ring. Whereas hydrolases were not suitable for resoluti

Synthesis, crystal structure and biological activity of ndichloroacetyl- 3,4-dihydro-3-methyl-2h-1,4-benzoxazines

A three-step sequence was developed for synthesizing N-dichloroacetyl-3,4-dihydro- 3-methyl-2H-1,4-benzoxazine. Compounds 4 were obtained via O-alkylation, reduction, cyclization and acylation with o-nitro phenol and chloroacetone as the starting material. The structures of the compounds were characterized by IR, 1H NMR, 13C NMR, MS spectroscopy and elemental analysis. The configuration of 4a was determined by Xray crystallography. The preliminary biological test showed that the compounds could protect maize against injury by acetochlor in some extent.

7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as Selective CB 2 cannabinoid receptor ligands: Structural investigations around a novel class of full agonists

Cannabinoid receptor agonists have gained attention as potential therapeutic targets of inflammatory and neuropathic pain. Here, we report the identification and optimization of a series of 7-oxo-[1,4]oxazino[2,3,4-ij] quinoline-6-carboxamide derivatives as a novel chemotype of selective cannabinoid CB2 receptor agonists. Structural modifications led to the identification of several compounds as potent and selective cannabinoid receptor agonists (20, hCB2Ki = 2.5 nM, SI = 166; 21, hCB2Ki = 0.81 nM, SI = 383; 38, hCB2K i = 15.8 nM, SI > 633; 56, hCB2Ki = 8.12 nM, SI > 1231; (R)-58, hCB2Ki = 9.24 nM, SI > 1082). The effect of a chiral center on the biological activity was also investigated, and it was found that the (R)-enantiomers exhibited greater affinity at the CB2 receptor than the (S)-enantiomers. In 3,5-cyclic adenosine monophosphate assays, the novel series behaved as agonists, exhibiting functional activity at the human CB2 receptor.

PROCESS FOR PREPARING ACYL AMIDE COMPOUNDS

A process for preparing acyl amide compounds is described, in which a recrystallized o-nitrophenoxy carbonyl compound is hydrogenated with hydrogen gas in the presence of a nickel sponge metal catalyst with ring closure to form a benzoxazine, which is then reacted with an acyl halide to give the corresponding acyl amide compound.

Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property). [Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive: wherein each symbol is as described in the specification.

Production Method of Nitrogen-Containing Fused Ring Compounds

[Problems] The present invention provides a superior production method and a superior purification method of compounds effective for the treatment or prophylaxis of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like. [Means] A compound represented by the following formula [2] or a pharmaceutically acceptable salt thereof can be produced by reacting a compound represented by the following formula [3] or a salt thereof with a compound represented by the following formula [4], a salt thereof or a reactive derivative thereof. Moreover, crystallization of a compound represented by the formula [2] can be performed with industrially superior workability, and high quality crystals of a compound represented by the formula [2] can be obtained. wherein each symbol is as defined in the description.

Nitrogen-containing fused ring compounds and use thereof

A URAT1 activity inhibitor containing a nitrogen-containing fused ring compound represented by the following formula [1]: wherein each symbol is as defined in the description. The present invention is useful for the prophylaxis or treatment of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like.

Method for making acylamides by synthesizing and acylating benzoxazines

A method is provided for synthesizing acylamides, useful as protectant for cultivated plants. A benzoxazine, such as 3,4-dihydro-3-methyl-2H-1,4-benzoxazine, is made in a stepwise manner by initially forming an o-nitrophenoxyketone by reacting a haloketone and a nitrophenol. The o-nitrophenoxyketone is hydrogenated to form the corresponding benzoxazine, which is thereafter acylated with an acylhalide to produce the acylamide, such as 4-dichloroacetyl-3,4-dichloroacetyl-3,4-dihydro-3-methyl-2H-1,4-benzoxazine.